A subclassification of intermediate-risk prostate cancer patients could lead to more precise guidelines and subsequently better clinical outcomes. We talked to Prof. Dr. Andreas Böhle about his recent paper on the matter.
Are you looking for something specific? Browse our categories to find the content you are looking for.
Are you interested in receiving the latest news on our products and recent developments? Do you want to stay updated regarding upcoming events? Our newsletter will be sent regularly and you can unsubscribe anytime.
Email Lists (please select at least one)
SUBSCRIBE TO OUR NEWSLETTER